Novel drug delivery system using human iPS cell technology for recognition of cancer-related antigen

点击翻译按钮获取中文摘要

Original aim of this study is to achieve the proof of concept for drug delivery system (DDS) using iPS cell technology. Idea is derived from the granule release in platelets (dense- or alpha-granule in platelets), whereby engineered megakaryocytes that express rearranged specific T cell receptor component to cancer-related antigen may be able to make unique type of DDS platelets. In that context, we have established T lymphocyte generation, particularly CD8 cytotoxic cells in addition to naive T cells from original antigen-specific CD8 T cells through iPS cells in human system (Cell Stem Cell, 2013). We also showed that iPS cell-derived megakaryocytes are capable of expressing TCR component, contributing to original concept in the future.